Breaking News, Promotions & Moves

Affinia Names Chief Medical Officer

Hideo Makimura is a drug developer with 20+ years of experience as a physician-scientist at biopharmaceutical companies and academia.

Author Image

By: Charlie Sternberg

Associate Editor

Hideo Makimura, M.D., Ph.D.

Affinia Therapeutics, a gene therapy company with a pipeline of adeno-associated virus (AAV) gene therapies for devastating cardiovascular and neurological diseases, has appointed Hideo Makimura, M.D., Ph.D., as its Chief Medical Officer. Makimura brings leadership experience in both early- and late-stage clinical research and development (R&D) in the biopharmaceutical industry and academic research, as well as complementary clinical practice expertise as an endocrinologist to Affinia. He...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics